Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 13, 2017. The document serves as a transaction notification regarding the acquisition of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions.
| Transaction Date | Instrument | Price per Share | Total Volume |
|---|---|---|---|
| October 12, 2017 | Ordinary Shares (25 pence each) | £15.2816 | 349 shares |
Note: The total volume of 349 shares represents the aggregate of individual transactions by eight executives.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine share acquisitions resulting from dividend reinvestment plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed on the London Stock Exchange (XLON) as part of the Company's Share Reward Plan following dividends paid on October 12, 2017.
Important Facts for Investors
- Transaction Nature: All reported transactions were acquisitions of ordinary shares via dividend reinvestment, not open market purchases or sales.
- Participants: Transactions involved eight senior executives, including the CEO (Ms E Walmsley), CFO (Mr S Dingemans), and President of R&D (Dr P J T Vallance).
- Share Price: The uniform execution price for all transactions was £15.2816 per share.
- Volume: Individual transaction volumes were small, ranging from 7 to 65 shares per executive.